title: EPO and super-EPO: erythropoietins direct neoangiogenesis by cardiac progenitor cells.
abstract: Erythropoietin, the red blood cell-making cytokine, is also a potential cytoprotective agent in heart disease. In this issue of Cell Stem Cell, Hoch et al. (2011) use two heart failure models, including chemotherapeutic cardiotoxicity, to reveal a mechanistic connection between reduced cardiomyocyte production of erythropoietin and neoangiogenesis by cardiac progenitors.
authors.affiliation: British Heart Foundation Centre of Research Excellence, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK. m.d.schneider@imperial.ac.uk
authors.forename: Michael D
authors.initials: MD
authors.lastname: Schneider
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002454:Cell Differentiation / Q000187:drug effects*; D042783:Endothelial Cells / Q000166:cytology*; D004921:Erythropoietin / Q000494:pharmacology*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D009206:Myocardium / Q000473:pathology*; D013234:Stem Cells / Q000166:cytology*
chemical_list: D000970:Antineoplastic Agents; D004921:Erythropoietin